



Third international workshop
on interim-PET in lymphoma
Closed session - Qualitative assessment

Unresolved issues related to Deauville 5 PS

Topic 1 Lead: Dr Kostagoklu

The assessment of marrow response

Measuring the 'normal' thresholds of MBP and liver –should it be purely visual, or combined with a semi-quantitative assessment e.g. SUVmax, SUVpeak or SUVmean to compare with the lesion of interest

Topic 2 Lead: Dr Mikhaeel

What is the best cut off to divide 'moderately' increased (score 4) and markedly increased (score 5) uptake. Can we better define the patients with clinically significant uptake within these groups?

Topic 3 Lead: Dr Hagenbeek

Is interim PET of clinical value in lymphomas other than HL and DLBCL? What does the oncologist want from an "early response" scan in different lymphomas?

Unresolved issues related to Deauville 5 PS

Topic 1

Lead: Dr Kostagoklu

The assessment of marrow response

Topic 2

Lead: Dr Mikhaeel

What is the best cut off to divide 'moderately' increased (score 4) and markedly increased (score 5) uptake. Can we better define the patients with clinically significant uptake within these groups?

Topic 3

Lead: Dr Hagenbeek

Is interim PET of clinical value in lymphomas other than HL and DLBCL? What does the oncologist want from an "early response" scan in different lymphomas?

Summary

- Clarify some omissions :

Propose written suggestions for assessment of marrow response

Score 5 and/or new lesions

Define subtypes of lymphoma where PET is useful and which are worthwhile of study

Should we explore use of DS for end PET?